Most teams look for “patent claims.” The winners look for “formulation escape hatches.”
If you’re in pharma strategy, BD, or competitive intelligence, you already know the obvious: patents can block a competitor’s path. But the real advantage isn’t jus…

Russia’s latest VED/SSM lists aren’t just regulatory housekeeping—they’re a timing tool. And if you’re a generic or biosimilar player, the difference between “early” and “too early” can be the difference between a successful launch and a costly stall.
…

🚨 Pharma pipelines don’t fail because of science. They fail because of freedom to operate.
If you’re building a drug program—whether it’s a reformulation, a new indication, a biosimilar, or a next-gen combination—your biggest hidden risk is often no…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Competitive Advantage
Most pharma conversations about generics start and end with the ANDA. It’s understandable: ANDAs are the workhorse for abbreviated approvals, and they’re often the fa…

Pharma IP teams are used to thinking in “years” and “filings.” But in Russia, the clock can move in ways that don’t always feel intuitive—especially when it comes to patent term extensions.
If you’re responsible for freedom-to-operate, portfolio strate…

Drug patent portfolios are often treated like static assets—filed, granted, and then quietly shelved. But in today’s litigation-aware landscape, that mindset is leaving value on the table. The real competitive advantage comes from building a portfolio …

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, “patent expiration” isn’t just a legal milestone. It’s a pricing event, a contracting event, and—if you’re prepared—a margin event. Yet…

Generic launches don’t “happen.” They arrive—on a calendar that’s been quietly built months (or years) earlier by patent filings, litigation milestones, regulatory timelines, and the fine print of exclusivity.
Most teams still forecast generic entry th…

Most people treat the FDA Orange Book like a static database—something you consult when you’re filing a patent challenge or tracking exclusivity.
But if you’re a business development leader, BD/sourcing professional, or anyone trying to find “hidden” p…

Biotech investors love to talk about “pipeline value.” But most portfolio rankings still boil down to a gut check: which program looks most exciting, which target is hottest, which team has the best story.
That’s understandable—until you realize excite…